Evidence map›Paper›PMID 31885880›Full record

ArticleImmunometabolism2020

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.

Paul Dent, Laurence Booth, Andrew Poklepovic

Open access · diamondAbstract read
In one paragraph

Article in Immunometabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Paul DentDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.
Laurence BoothDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.
Andrew PoklepovicDepartment of Medicine, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.
Virginia Commonwealth University · US

Funding

Pemetrexed and sildenafil for lung cancerR01CA192613 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 2015 to 2019
$1.6M
NCI NIH HHS R01 CA192613
6 · The paper itself

Abstract

LC3-associated phagocytosis, a distinct form of autophagy, plays a key role in antigen presentation. Autophagy itself plays a central role in the regulation of cellular metabolism. Proteins that regulate autophagy include the AMPK which senses high levels of AMP, and mTOR, which integrates amino acid and fatty acid metabolism with autophagy. More recently, autophagy has been demonstrated to regulate tumor cell immunogenicity via the degradation of histone deacetylase proteins. Individual drugs and drug combinations that activate the ATM-AMPK pathway and inactivate mTOR, cause autophagosome formation. The maturation of autophagosomes into autolysosomes causes the autophagic degradation of histone deacetylase proteins who regulate the transcription of PD-L1, Class I MHCA, ODC and IDO1. Indeed, drug combinations that do not contain an HDAC inhibitor can nevertheless act as de facto HDAC inhibitors, via autophagic degradation of HDAC proteins. Such drug combinations simultaneously kill tumor cells via immunogenic autophagy and in parallel opsonize tumor cells to checkpoint inhibitor immunotherapies via reduced expression of PD-L1, ODC and IDO1, and increased expression of Class I MHCA.

Indexed as

apoptosisautophagychaperonedrugendoplasmic reticulumERKhistone deacetylaseimmunotherapykinaseLC3-associated phagocytosisMAP kinaseneratiniboff-target effectpazopanibpemetrexedreceptor tyrosine kinasesildenafilsurvival signaling

Identifiers

PMID31885880
PMCPMC6934083
OpenAlexW2993949309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.